# Special Issue

# PET and MRI Radiomics in Cancer Predictive Modeling

### Message from the Guest Editors

Today, radiomics has become an important part of cancer research, and imaging is obviously a crucial tool for the management of cancer patients. For the present Special Issue, we wish to focus on the contributions of radiomics and machine (deep) learning developments dedicated to the use of PET images and MRI multimodal-sequence-derived modeling (obtained either in sequential/simultaneous PET/MRI integrated scanners or separated machines) for cancer applications, including diagnosis (e.g., virtual biopsy, staging), prognosis (e.g., risk stratification, survival analysis), therapy response assessment and predictive modeling (e.g., response to therapy prediction relying on before/during/after imaging), and relationships or combinations with other -omics (e.g., radiogenomics). We call for papers dedicated to the development of methods for image analysis and processing, integration of machine/deep learning developments within the radiomics framework, and clinically-relevant studies in patient cohorts regarding various endpoints for all types of cancer for which PET and/or MRI images play a significant role (e.g., brain, cervical, rectum, head and neck).

### Guest Editors

Dr. Mathieu Hatt

Prof. Catherine Cheze Le Rest

Dr. Ulrike Schick

Dr. Thomas C Booth

### Deadline for manuscript submissions

closed (31 July 2022)

**Cancers**

**an Open Access Journal by MDPI**

**Impact Factor 4.4**
**CiteScore 8.8**
**Indexed in PubMed**

mdpi.com/si/48754

*Cancers*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

# Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

# About the Journal

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)